Renol Polychem (RNPL)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 46.09% indicates highly efficient use of capital.
• Sales growth of 38.81% shows strong demand momentum.
• Piotroski F-Score of 7/9 suggests sound fundamentals and financial health.
• Promoter holding of 51.10% aligns management interests with minority shareholders.
• PEG of 0.92 offers relative value if earnings growth accelerates.

Concerns

• Profit growth of only 8.18% lags far behind sales growth, indicating margin pressure.
• P/E of 21.62 is not cheap given current profit growth; the valuation depends on future acceleration.
• No dividend yield; total return depends entirely on capital appreciation.
• Missing data on book value, debt/equity, and ROE limits a Graham-style margin-of-safety assessment.

AI Analysis

When I look at Renol Polychem, I see a small specialty chemical player with some encouraging signs, but also enough missing numbers to keep me cautious. The high ROCE of 46.09% is striking; it suggests the business generates strong returns on capital employed, a quality I admire. Sales grew 38.81%, which shows demand momentum, and the Piotroski F-Score of 7 out of 9 points to solid fundamentals—profitability, leverage, and efficiency are generally healthy. Promoter holding of 51.10% aligns interests. However, I cannot call it a wide-moat business from these numbers alone. Specialty chemicals can have customer stickiness, but there is no margin-of-safety in intangibles visible here. The latest quarter: sales ₹40 Cr, net profit ₹2 Cr. Annualised, that is ~₹8 Cr against market cap ₹112 Cr, a reasonable earnings yield if maintained, but trailing P/E of 21.62 and profit growth of only 8.18% give me pause. Sales are racing ahead while profit lags—that tells me margins are under pressure, perhaps from raw material costs or competition. A PEG of 0.92 is attractive only if the earnings growth actually accelerates; based on current 8% profit growth, the P/E is not obviously cheap. Zero dividend means shareholders rely entirely on capital appreciation. I also have no book value, debt/equity, or ROE data—Graham would insist on knowing the balance sheet before parting with capital. I'd want to see whether the 38% sales growth converts into profit, whether ROCE stays near 46%, and whether the company can fund growth without leverage. At ₹134 near the upper half of its 52-week range, the market is already expecting good things. This is a promising fast grower, but I would wait for better evidence of earnings delivery and a clearer balance sheet before making a commitment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer